XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Considerations (Tables)
12 Months Ended
Jun. 30, 2020
Fair Value Disclosures [Abstract]  
Fair value on a recurring basis
  Fair Value Measurements at June 30, 2020
    Total      Quoted Priced in Active Markets for Identical Assets (Level 1)      Significant Other Observable Inputs (Level 2)      Significant Unobservable Inputs(Level 3)  
 Recurring:                        
 Warrant derivative liability   11,000                 11,000  
 Contingent consideration     13,588,000                   13,588,000  
     CVR liability     5,572,000                   5,572,000  
    $ 19,171,000                 $ 19,171,000  

 

  Fair Value Measurements at June 30, 2019
   

 

Total

   

 Quoted Priced in Active Markets for Identical Assets

(Level 1)

   

 Significant Other Observable Inputs

(Level 2)

   

 Significant Unobservable Inputs

(Level 3)

 
 Recurring:                        
 Warrant derivative liability   $ 13,000                 $ 13,000  
 Contingent consideration     23,326,000                   23,326,000  
    $ 23,339,000                 $ 23,339,000  

 

Significant assumptions in valuing the warrant derivative liability
   

As of

June 30, 2020

     As of
June 30, 2019
   

At

Issuance

 
 Warrant Derivative Liability                  
 Volatility     163.2 %     163.2 %     188.0 %
 Equivalent term (years)     2.13       3.13       5.00  
 Risk-free interest rate     0.16 %     1.83 %     1.83 %
 Dividend yield     0.00 %     0.00 %     0.00 %
Reconciliation of changes in the warrant derivative liability
     Liability Classified Warrants  
       
 Balance as of June 30, 2018   $ 94,000  
    Change in fair value included in earnings     (81,000 )
 Balance as of June 30, 2019   $ 13,000  
    Change in fair value included in earnings     (2,000 )
 Balance as of June 30, 2020   $ 11,000  
Changes in the contingent consideration
     Contingent Consideration  
       
 Balance as of June 30, 2018   $ 4,694,000  
     Increase due to purchase of assets     8,833,000  
     Increase due to accretion     516,000  
     Decrease due to contractual payment     (548,000 )
     Increase due to remeasurement     9,831,000  
 Balance as of June 30, 2019   $ 23,326,000  
     Increase due to purchase of assets     183,000  
     Increase due to accretion     789,000  
     Decrease due to contractual payment     (180,000 )
     Decrease due to amended license agreement     (5,200,000 )
     Decrease due to remeasurement     (5,330,000 )
 Balance as of June 30, 2020   $ 13,588,000  
Assumption for valuing contingent consideration
   

As of

June 30, 2020

   

As of

June 30, 2019

 
 Natesto            
 Relevered Beta           0.83  
 Market risk premium           5.50 %
 Risk-free interest rate           3.50 %
 Discount           5.20 %
 Company specific discount           5.00 %

 

   

As of

June 30, 2020

   

As of

June 30, 2019

 
 ZolpiMist            
 Relevered Beta     1.17       1.16  
 Market risk premium     6.00 %     5.50 %
 Risk-free interest rate     3.00 %     3.50 %
 Discount     5.20 %     5.20 %
 Company specific discount     5.00 %     5.00 %

 

   

As of

June 30, 2020

   

As of

June 30, 2019

 
 Tuzistra            
 Relevered Beta     0.36       1.19  
 Maket risk premium     6.00 %     5.50 %
 Risk-free interest rate     3.00 %     3.50 %
 Discount     5.20 %     5.20 %
 Company specific discount     15.00 %     15.00 %

 

Fair value on a nonrecurring basis
    Fair Value Measurements at June 30, 2020  
   

 Fair Value at

Measurement Date

   

 Quoted Priced in Active Markets for Identical Assets

(Level 1)

   

 Significant Other Observable Inputs

(Level 2)

   

 Significant Unobservable Inputs

(Level 3)

 
 Non-recurring                        
 MiOXSYS patent (Luoxis patents)   $ -     $ -     $ -     $ -  
 Debt      982,079        -        -        982,076  
                                 
 Pediatric Portfolio (November 1, 2019)                                
 Product technology rights   22,700,000                 22,700,000  
 Goodwill     19,453,135                   19,453,135  
 Fixed payment arrangements     29,837,853                   29,837,853  
                                 
 Innovus Merger (February 14, 2020)                                
 Customer lists     390,000                   390,000  
 Product distribution righs (trademarks and patents)     11,354,000                   11,354,000  
 Goodwill     8,637,272                   8,637,272  
 Notes payable     3,056,361                   3,056,361  
                                 
    $ 96,410,697     $     $     $ 96,410,697  
Significant assumptions in valuing intangible assets
   

As of

November 1,

2019 (*)

 
 Product technology rights      
 Re-levered Beta     1.60  
 Market risk premium     6.00 %
 Small stock risk premium     5.20 %
 Risk-free interest rate     2.00 %
 Company specific discount     25.00 %

 

(*) Valuation performed as of November 1, 2019. As a non-recurring fair value measurement, there is no remeasurement at each reporting period unless indications exist that the fair value of the asset has been impaired. There were no indicators as of June 30, 2020 that the fair value of the Product technology rights was impaired.

 

   

As of

February 14,

2020

 
 Trademarks and patents      
 Re-levered Beta     0.84 %
 Market risk premium     6.17 %
 Small stock risk premium     4.99 %
 Risk-free interest rate     1.89 %
 Company specific discount     20.00 %
Fixed payment obligations discount rate
   

As of November 1,

2019 (≠)

 
 Fixed payment obligations    
 Discount rate    1.8% to 12.4%  

 

(≠) Valuation performed as of November 1, 2019. As a non-recurring fair value measurement, there is no remeasurement at each reporting period unless indicates that the circumstances that existed as of the November 1, 2019 measurement date indicate that the carrying value is no longer indicative of fair value.

 

Changes in Level 3 inputs
     Product Technology Rights      Innovus Assets      Goodwill      Liability Classified Warrants      CVR Liability      Contingent Consideration      Fixed Payment Arrangements  
 Balance as of June 30, 2019               13,000         $ 23,326,000      
 Transfers into Level 3                                          
 Transfer out of Level 3                                          
 Total gains, losses, amortization or accretion in period                                          
 Included in earnings     (1,513,000 )     (663,000 )           (2,000 )     523,000       (9,741,000 )     1,452,000  
 Included in other comprehensive income                                              
 Purchases, issues, sales and settlements                                                      
 Purchases     22,700,000       11,744,000       28,090,000             7,049,000       183,000        
 Issues                                         29,838,000  
 Sales                                          
 Settlements                             (2,000,000 )     (180,000 )     (17,778,000 )
 Balance as of June 30, 2020   21,187,000     11,081,000     28,090,000     11,000     5,572,000     13,588,000     13,512,000